Teva expected to pay big bucks for decision to use oversized vials

Teva Pharamaceuticals ($TEVA) is discovering size matters. The Israeli generics giant reportedly is setting aside $285 million to settle lawsuits alleging the jumbo-sized vials it used for its anesthetic propofol encouraged re-use and led to colonoscopy patients developing hepatitis C. The company no longer makes the drug. The money will settle about 120 lawsuits, mostly from patients of a Nevada colonoscopy center. It will also settle a case in which it faced a $500 million jury award. Story

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.